Cognito Therapeutics develops non-invasive treatments for Alzheimer's disease by targeting abnormal neuronal activity in the brain.

Cognito Therapeutics

Cognito Therapeutics is a pioneer in non-invasive neuromodulation to treat neurodegenerative diseases and improve human cognitive performance. The company has completed multiple clinical studies demonstrating its investigational therapeutic has the potential to safely slow or stop cognitive decline and loss of brain volume in Alzheimer’s disease. 

Cognito has received FDA Breakthrough Device Designation for the treatment of Alzheimer’s disease and expects to start pivotal studies in 2022. The company’s technology was based on pioneering optogenetics research by scientific co-founders Professors Li-Huei Tsai and Ed Boyden at MIT.

FoundersX Ventures

Starbloom Capital

WS Investment Company

IAG Capital Partners

Alzheimer's Drug Discovery Foundation

OpAmp Capital

Cognito Therapeutics, Inc.

Join our next Zoom In on Dementia & Alzheimer’s episode on Aug 1, where we’ll talk with Cognito Therapeutics, Inc. CEO Brent Vaughan about the HOPE Study, clinical research exploring if a non-invasive wearable device could slow the progression of mild to moderate Alzheimer’s disease. 

Visit BrightFocus.org/ZoomIn to learn more and register.

#Alzheimers #Research #Health

Excited to share these new findings for our disease modifying therapy Spectris at the Alzheimer's Association® International Conference 2024. #AAIC24 🧠🧠

- Spectris AD™ meaningfully reduced functional and cognitive decline in Alzheimer’s Disease over 6 months compared to sham treatment and was associated with 60-84% time savings.

- OVERTURE I Phase 2 MRI analysis demonstrated reduced corpus callosum atrophy over 6 months.

“This new post hoc analysis from our OVERTURE I study highlight Spectris’ ability to significantly slow the decline in daily function and cognition in patients with #Alzheimer’s, potentially offering patients more time to maintain their independence and quality of life,” said Ralph Kern, M.D., MHSc, Chief Medical Officer, Cognito Therapeutics. “These results reinforce our commitment to bring a novel disease-modifying therapy to patients, as we continue to enroll patients in our HOPE pivotal trial.”

Read the release:

https://lnkd.in/eA2c9xAU

In the latest episode of our podcast, Christian Howell, Chief Commercial Officer at Cognito Therapeutics, shares his experience in implementing value-based healthcare models and offers unique perspectives on driving innovation while developing novel therapies.

🎙️ Learn about:
🔹 The importance of stakeholder engagement in healthcare innovation
🔹 Fostering a culture of smart risk-taking and learning from failures
🔹 Practical lessons for innovation from value-based healthcare models

🔗 Listen now: https://lnkd.in/dv-3YCRh

Thanks MassDevice for featuring Cognito as one of the 7 #neurotech companies to know! 🧠🧠🧠

Since bringing in a $73 million Series B last year, Cognito Therapeutics has delivered multiple positive study updates for its non-invasive neuromodulation technology.

The Cambridge, Massachusetts–based company’s Spectris system could provide disease-modifying therapy for treating Alzheimer’s disease. Its non-invasive neuromodulation device delivers proprietary gamma frequency light and sound stimulation. This evokes EEG-confirmed gamma frequency brain oscillations to treat central nervous system (CNS) diseases.

Early results suggest that combined Spectris outcomes fall in line with published criteria for disease modification. Cognito said the data supports early treatment as well.

Dr. Ralph Kern, chief medical officer of Cognito Therapeutics, said: “This innovative therapy has the potential to be seamlessly integrated as a home-based treatment into the lives of patients and caregivers.”

https://lnkd.in/gHRyN3Vi

Excited to share our CSO Mihaly Hajos will be presenting a talk on July 27th at #AAIC24: "Evoked Gamma Oscillation (Spectris) as a Potential Therapeutic Intervention for Alzheimer's Disease." 

Hope you can join us at the Alzheimer's Association®International Conference later this month! 

#Alzheimers #cognition #neuroscience

Terrific discussion on what it takes to progress science with Teresa Bitetti Takeda Sekar (Sek) Kathiresan Verve Therapeutics John Lepore ProFound Therapeutics Søren Møller Novo Holdings Joanna Stanicka Axonis Therapeutics Brent Vaughan Cognito Therapeutics, Inc.

Metric
Company Name	Cognito Therapeutics
Symbol
MSH ID	COM:COGNITOTX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biotechnology
Country	US
Stage
Employee Count	52
Website	cognitotx.com
LinkedIn	cognito-therapeutics-inc.
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:COGNITOTX

Cognito Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue